News Search Results
Feb 06, 2026, 08:00 ET Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical
More news about: Insilico Medicine
Feb 06, 2026, 07:00 ET Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB)
More news about: Delonix Bioworks
Feb 05, 2026, 12:35 ET Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
Mass., Feb. 5, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a privately held, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zenocutuzumab‑zbco for the
More news about: Partner Therapeutics, Inc.
Feb 05, 2026, 11:05 ET Active Implantable Medical Devices Market Poised for Strong Growth as Technological Innovation and Chronic Disease Burden Accelerate Adoption: Verified Market Research®
Sirona, Allergan Inc., Boston Scientific Corporation, BIOTRONIK SE & Co. KG, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co., Ltd.Market SegmentationThe Active Implantable Medical Devices Market is segmented based on:By
More news about: Verified Market Research
Feb 05, 2026, 10:59 ET K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO
K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced completion of dosing in the first patient
More news about: K36 Therapeutics
Feb 05, 2026, 10:01 ET Nanorobotics Market worth $4.52 billion by 2032 - Exclusive Report by MarketsandMarkets™
are accelerating interest in nano-enabled surgical solutions. In addition, expanding clinical research and strong investment from healthcare and biotechnology companies are supporting the rapid development of nanorobotics for nano surgery and tissue repair, positioning this application segment as the fastest-growing
More news about: MarketsandMarkets
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ: ONCY), Relay Therapeutics (NASDAQ: RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ: ZLAB), and Arrivent BioPharma (NASDAQ: AVBP) directly at the convergence of urgent unmet medical
More news about: USA News Group
Feb 05, 2026, 09:15 ET Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
www.webull.com.About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Feb 05, 2026, 08:37 ET Global Soluble Corn Fiber Market Set to Eclipse USD 78.6 Billion by 2036 as Functional Food Reformulation Hits Critical Mass | Future Market Insights'
and lower the environmental footprint of production.At the same time, regional players such as Baolingbao Biology and Jianlong Biotechnology are expanding the market's reach in East Asia, offering localized solutions that cater to specific regional palates and regulatory standards.The
More news about: Future Market Insights
Feb 05, 2026, 08:00 ET Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors
BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ - Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant
More news about: Providence Therapeutics Holdings Inc
Feb 05, 2026, 08:00 ET Braveheart Bio Announces Senior Leadership Appointments to Strengthen Scientific and Operational Capabilities While Advancing Global Phase 3 Development
SAN FRANCISCO, Feb. 5, 2026 /PRNewswire/ -- Braveheart Bio, a clinical-stage biotechnology company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, today announced that
More news about: Braveheart Bio
Feb 05, 2026, 08:00 ET Calico Appoints Joseph R. Arron, M.D., Ph.D., as Head of Human Biology and Genetics
FRANCISCO, Calif., Feb. 5, 2026 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a clinical-stage biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, Ph.D., today announced the appointment
More news about: Calico Life Sciences LLC
Feb 05, 2026, 08:00 ET Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
60 to 200 molecules synthesized and tested in each program.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Feb 05, 2026, 05:47 ET Tanmiah Partners with PHYLA and RECYCLEE to Bolster Circular Economy and Food Security
producers, today announced the signing of two strategic Memorandums of Understanding (MoUs) with SEQUENCIVE sustainability portfolio companies: PHYLA, a biotechnology company pioneering the production of sustainable alternative protein, and RECYCLEE, a digital waste management solutions provider.
More news about: Tanmiah Food Company
Feb 05, 2026, 05:45 ET Tanmiah Partners with PHYLA and RECYCLEE to Bolster Circular Economy and Food Security
producers, today announced the signing of two strategic Memorandums of Understanding (MoUs) with SEQUENCIVE sustainability portfolio companies: PHYLA, a biotechnology company pioneering the production of sustainable alternative protein, and RECYCLEE, a digital waste management solutions provider.
More news about: Tanmiah Food Company
Feb 05, 2026, 04:09 ET HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at major international oncology
More news about: HanchorBio Inc.
Feb 05, 2026, 03:47 ET Proteomics Market Growing at an 11.87% CAGR to 2031 as Precision Medicine & Drug Discovery Adoption Rise, Says a 2026 Mordor Intelligence Report
proteomics market, driven by strong investment in biomedical research, advanced laboratory infrastructure, and the presence of major pharmaceutical and biotechnology companies. The region continues to adopt proteomics technologies across research, clinical, and commercial settings to support innovation in drug
More news about: Mordor Intelligence Private Limited
Feb 04, 2026, 17:31 ET Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Oncolys Biopharma, EpicentRx, Theriva Biologics, Lokon Pharma, DNAtrix, Surv BioPharma Inc., Treovir, Immvira Pharma, Virogin Biotech, OrienGene Biotechnology, Apices Soluciones, Vyriad, Transgene, BioEclipse Therapeutics, Imugene, CG Oncology, Istari Oncology, Akamis Bio, Elicera Therapeutics, and
More news about: DelveInsight Business Research, LLP
Feb 04, 2026, 16:55 ET Federal Funding Bill Commits $3 Million to Versiti Blood Research Institute Expansion
Wisconsin and the nation."VBRI is recognized as one of the world's leading blood health research centers, connecting global scientists, biotechnology partners, and federal research support in service of discovery. VBRI researchers develop treatments that save lives on battlefields, in operating
More news about: Versiti, Inc.
Feb 04, 2026, 12:51 ET Lupin Launches Topiramate Extended-Release Capsules in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Inc.
Feb 04, 2026, 10:39 ET Seed Treatment Fungicides Market Surges to USD 9.8 Billion by 2033, Propelled by 4.8% CAGR - Verified Market Reports®
competitive advantage.Strategic partnerships and IP-led innovation: Collaborations between agrochemical companies, seed producers, and biotechnology firms are intensifying. Intellectual property around formulation science and biological strains is becoming a key differentiator, influencing long-term
More news about: Verified Market Reports
Feb 04, 2026, 10:20 ET Finally, a Natural Alternative to Acacia Gum in Beverages
www.FiberstarIngredients.com is a privately held innovative biotechnology Company focused on enhancing food performance by manufacturing and marketing value-added, plant-based food ingredients. Its largest brand, Citri-Fi®,
More news about: Fiberstar, Inc.
Feb 04, 2026, 10:19 ET Finally, a Natural Alternative to Acacia Gum in Beverages
www.FiberstarIngredients.com is a privately held innovative biotechnology Company focused on enhancing food performance by manufacturing and marketing value-added, plant-based food ingredients. Its largest brand, Citri-Fi®,
More news about: Fiberstar, Inc.
Feb 04, 2026, 09:02 ET Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
here.About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Feb 04, 2026, 09:00 ET LifeNet Health Achieves ISO 9001:2015 Certification, Advancing High-Quality Research That Expands Access to Healthcare Innovation
successfully completed an ISO 9001:2015 Quality Management System (QMS) certification, strengthening its ability to support pharmaceutical and biotechnology partners in developing safe, effective solutions that improve lives and expand access to healthcare.
More news about: LifeNet Health